Bionik Laboratories Corp. has announced a partnership with the University of Texas at Dallas to license robotics and control systems technology, according to a press release.
The 1-year agreement allows Bionik to review technology developed at the University of Texas at Dallas, gives the company the option to negotiate an exclusive, worldwide license under certain patent rights owned by the university and an option to negotiate a non-exclusive license under certain technology rights owned by the university.
Michal Prywata, BEng, co-founder, chief technology officer and director of Bionik, said in the release, “We entered into this option agreement as our preliminary investigation has indicated that this infusion of technology and innovation will provide a strong, competitive advantage to our current technology platform, and that the company can extend its exoskeleton robotic platform and improve our existing technology.”
The technology has been developed by Robert Gregg IV, PhD, and University of Texas at Dallas PhD students Ge Lv and Hanqi Zhu. Gregg is an assistant professor of bioengineering and mechanical engineering and director of the Locomotor Control Systems Laboratory at the university and the University of Texas Southwestern Medical Center.
“We are pleased to work with an innovative company such as Bionik Laboratories so that the results of our research can benefit the most people,” Gregg said in the release. “These innovations in control systems and novel actuation technologies improve robotic performance and will ultimately produce better mobility for a larger patient population. During Bionik’s option period and on execution of the final license agreement, we will work closely with Bionik to advance the technology that will allow them to enhance and commercialize their assistive robotics solution and improve quality of life for persons with these disabilities.”
References:
Disclosures
: Gregg and Prywata report no relevant financial disclosures.
